Christopher J. Nardo
CIK 1870247 · View on SEC EDGAR ↗
First SEC filing: Aug. 12, 2021 · Latest: Aug. 12, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 3, 2022 | DRMAW | A | 30,000 | — | — | 30,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Aug. 17, 2021 | DRMAW | C | 50,000 | — | — | 0 Indirect | -100.00% | Disposed | (price as of 2026-08-20) |
| Aug. 17, 2021 | DRMAW | C | 2,439 | — | — | 2,439 Indirect | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 3, 2022 | DRMAW | Stock Option (right to buy) | Common Stock (30,000) | $1.88 | Jan. 2, 2032 | 30,000 | Acquired |
| Aug. 17, 2021 | DRMAW | Series 1 Preferred Stock | Common Stock (2,439) | — | — | 50,000 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 8 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 12, 2021 | DRMAW | Common Stock | 25,121 | Direct |
| Aug. 12, 2021 | DRMAW | Stock Option (Right to Buy)→ Common Stock | — | Direct |
| Aug. 12, 2021 | DRMAW | Stock Option (Right to Buy)→ Common Stock | — | Direct |
| Aug. 12, 2021 | DRMAW | Stock Option (Right to Buy)→ Common Stock | — | Direct |
| Aug. 12, 2021 | DRMAW | Stock Option (Right to Buy)→ Common Stock | — | Direct |
| Aug. 12, 2021 | DRMAW | Stock Option (Right to Buy)→ Common Stock | — | Direct |
| Aug. 12, 2021 | DRMAW | Stock Option (Right to Buy)→ Common Stock | — | Direct |
| Aug. 12, 2021 | DRMAW | Series 1 Preferred Stock→ Common Stock | — | Indirect |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $336,000 | $107,520 | — | $26,450 | — | — | — | $469,970 |
| 2022 | $297,917 | $32,000 | — | $63,390 | — | — | — | $393,307 |
| 2021 | $270,000 | $86,400 | — | $322,504 | — | — | — | $678,904 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.